Comments on: Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy
- 26 June 2026
- journal article
- letter
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 217 (3)
Abstract
This correspondence comments on LeVee et al.'s real-world study of neoadjuvant chemo-immunotherapy in early-stage triple-negative breast cancer. We highlight diabetes as a potentially modifiable host-state factor influencing pathologic complete response and propose a metabolic immunotherapy-readiness framework integrating glycaemic control, treatment delivery, endocrine monitoring, and equity-focused implementation. This perspective aims to support globally applicable strategies for improving chemo-immunotherapy effectiveness and access.Keywords
This publication has 3 references indexed in Scilit:
- Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: a multi-institution studyBreast Cancer Research and Treatment, 2026
- Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast CancerNew England Journal of Medicine, 2024
- Identification of Immune Checkpoint Inhibitor–Induced DiabetesJAMA Oncology, 2024